SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Down 42.8% in February

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 67,700 shares, a drop of 42.8% from the January 31st total of 118,400 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average trading volume of 127,400 shares, the days-to-cover ratio is presently 0.5 days.

SAB Biotherapeutics Stock Down 8.8 %

SABS traded down $0.15 on Monday, hitting $1.56. 31,799 shares of the company’s stock traded hands, compared to its average volume of 152,387. SAB Biotherapeutics has a one year low of $1.53 and a one year high of $6.30. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. The company’s 50 day simple moving average is $2.87 and its 200-day simple moving average is $3.00.

Analysts Set New Price Targets

A number of analysts have commented on SABS shares. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.40.

Institutional Investors Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. HB Wealth Management LLC boosted its position in shares of SAB Biotherapeutics by 118.6% during the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after acquiring an additional 128,800 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of SAB Biotherapeutics by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after buying an additional 12,692 shares in the last quarter. Diadema Partners LP bought a new position in shares of SAB Biotherapeutics during the 4th quarter valued at approximately $114,000. Kovitz Investment Group Partners LLC bought a new position in SAB Biotherapeutics during the third quarter valued at $52,000. Finally, Northern Trust Corp purchased a new position in SAB Biotherapeutics in the fourth quarter worth about $43,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.